dc.contributor.author |
García Lescano, Héctor Hugo |
|
dc.contributor.author |
Gonzales, Isidro |
|
dc.contributor.author |
Bustos Palomino, Javier Arturo |
|
dc.contributor.author |
Saavedra Pastor, Herbert |
|
dc.contributor.author |
Gavidia, Martin |
|
dc.contributor.author |
Rodriguez, Lourdes |
|
dc.contributor.author |
Najar Trujillo, Nestor Enrique |
|
dc.contributor.author |
Umeres, Hugo |
|
dc.contributor.author |
Pretell, E. Javier |
|
dc.date.accessioned |
2019-02-06T14:59:07Z |
|
dc.date.available |
2019-02-06T14:59:07Z |
|
dc.date.issued |
2015 |
|
dc.identifier.uri |
https://hdl.handle.net/20.500.12866/5556 |
|
dc.description.abstract |
We thank Aba Mahamat and colleagues for their comments on our Article1 and patient data illustrating a difficult case successfully treated with combined albendazole and praziquantel. We do not deem use of the combination a “shift”, rather a refinement in use of antiparasitic treatment to destroy viable brain parasites, which has been in use for more than 25 years. We certainly agree that antiparasitic treatment in neurocysticercosis should be individualised and not used as a blanket recipe... |
en_US |
dc.language.iso |
eng |
|
dc.publisher |
Elsevier |
|
dc.relation.ispartofseries |
Lancet. Infectious Diseases |
|
dc.rights |
info:eu-repo/semantics/restrictedAccess |
|
dc.rights.uri |
https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es |
|
dc.subject |
Female |
en_US |
dc.subject |
Humans |
en_US |
dc.subject |
Male |
en_US |
dc.subject |
Anthelmintics/therapeutic use |
en_US |
dc.subject |
Albendazole/therapeutic use |
en_US |
dc.subject |
Neurocysticercosis/drug therapy |
en_US |
dc.subject |
Praziquantel/therapeutic use |
en_US |
dc.title |
Combined antiparasitic treatment for neurocysticercosis - Authors' reply |
en_US |
dc.type |
info:eu-repo/semantics/article |
|
dc.identifier.doi |
https://doi.org/10.1016/S1473-3099(15)70047-2 |
|
dc.subject.ocde |
https://purl.org/pe-repo/ocde/ford#3.03.08 |
|
dc.relation.issn |
1474-4457 |
|